Design and synthesis of new symmetrical derivatives of dihydropyridine containing a pyridyl group on the 3, 5-positions and evaluation of their cytotoxic and multidrug resistance reversal activity

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 11, 2008, Pages 1481-1489

  Foroughinia, Farzaneh ^a   Javidnia, Katayoun ^a,b   Amirghofran, Zahra ^a,c   Mehdipour, Ahmadreza ^a   Miri, Ramin ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE; 3,5 DI (PYRIDIN 2 YLPROPYL) 2,6 DIMETHYL 4 (3 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; 3,5 DI (PYRIDIN 2 YLPROPYL) 2,6 DIMETHYL 4 (4 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; 3,5 DI (PYRIDIN 3 YLPROPYL) 2,6 DIMETHYL 4 (1 METHYL 5 NITROIMIDAZOL 2 YL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; 3,5 DI (PYRIDIN 3 YLPROPYL) 2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; 3,5 DI (PYRIDIN 3 YLPROPYL) 2,6 DIMETHYL 4 (3 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; 3,5 DI (PYRIDIN 3 YLPROPYL) 2,6 DIMETHYL 4 (4 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; 3,5 DI (PYRIDIN 4 YLPROPYL) 2,6 DIMETHYL 4 (1 METHYL 5 NITROIMIDAZOL 2 YL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; 3,5 DI (PYRIDIN 4 YLPROPYL) 2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; 3,5 DI (PYRIDIN 4 YLPROPYL) 2,6 DIMETHYL 4 (3 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; 3,5 DI (PYRIDIN 4 YLPROPYL) 2,6 DIMETHYL 4 (4 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; CALCIUM CHANNEL; DIHYDROPYRIDINE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLYCOPROTEIN P; MITOXANTRONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAJI CELL;

EID: 54949086756     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.11.0009     Document Type: Article

References (33)

1. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., Gottesman, M. M. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39: 361-398
2. Amini, M., Golabchifar, A. A., Dehpour, A. R., Pirali, H. M., Shafiee, A. (2002) Synthesis and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing dichloroimidazolyl substituents. Arzneimittelforschung 52: 21-26
3. Burden, D. A., Osheroff, N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400: 139-154
4. Clemens, R. J., Hyatt, H. A. (1985) Acetoacetylation with 2,2,6-trimethyl-4H-1,3-dioxin-4-one: a convenient alternative to diketene. J. Org. Chem. 50: 2431-2435
5. Dagnino, L., Li-Kwong-Ken, M. C., Wynn, H., Wolowyk, M. W., Triggle, C. R., Knaus, E. E. (1987) Synthesis and calcium channel antagonist activity of dialkyl 4-(dihydropyridinyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylates. J. Med. Chem. 30: 640-646
6. Fusi, F., Saponara, S., Valoti, M., Dragoni, S., D'Elia, P., Sgaragli, T., Alderighi, D., Kawase, M., Shah, A., Motohashi, N., Sgaragli, G. (2006) Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives. Curr. Drug Targets 7: 949-959
7. Gudmundsson, O., Stouch, T. R. (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev. 54: 315-328
8. Harker, W. G., Slade, D. L., Dalton, W. S., Meltzer, P. S., Trent, J. M. (1989) Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49: 4542-4549
9. Hosseini, M., Miri, R., Amini, M., Mirkhani, H., Hemmateenejad, B., Ghodsi, S., Alipour, E., Shafiee, A. (2007) Synthesis, QSAR and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing 1-methyl-4,5-dichloroimidazolyl substituents. Arch. Pharm. (weinheim). 340: 549-556
10. Jabbar, S. A. B., Twentyman, P. R., Watson, J. V. (1989) The MTT assay underestimates the growth inhibitory effects of interferons. Br. J. Cancer. 60: 523-528
11. Ji, B. S., He, L., Liu, G. Q. (2005) Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Life Sci. 77: 2221-2232
12. Kawase, M., Motohashi, N. (2003) New multidrug resistance reversal agents. Curr. Drug Targets. 4: 31-43
13. Kawase, M., Shah, A., Gaveriya, H., Motohashi, N., Sakagami, H., Varga, A., Molnar, J. (2002) 3,5-Dibenzoyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells. Bioorg. Med. Chem. 10: 1051-1055
14. Kiue, A., Sano, T., Suzuki, K., Inada, H., Okumura, M., Kikuchi, J., Sato, S., Cono, K., Kuwano, M. (1990) Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. Cancer Res. 50: 310-317
15. Liscovitch, M., Lavie, Y. (2002) Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 349-355
16. Mehdipour, A. R., Javidnia, K., Hemmateenejad, B., Amirghofran, Z., Miri, R. (2007) Dihydropyridine derivatives to overcome atypical multidrug resistance: design, synthesis, QSAR studies, and evaluation of their cytotoxic and pharmacological activities. Chem. Biol. Drug. Des. 70: 337-346
17. Miri, R., Javidnia, K., Sarkarzadeh, H., Hemmateenejad, B. (2006) Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist. Bioorg. Med. Chem. 14: 4842-4849
18. Molnár, J., Szabo, D., Mandi, Y., Mucsi, I., Fischer, J., Varga, A., König, S., Motohashi, N. (1998) Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds. Anticancer Res. 18: 3033-3038
19. Morrow, C. S., Cowan, K. H. (1997) Drug resistance and its clinical circumvention. In: Holland, J. F., Frei, E., Bast, J. C., Kufe, D. W., Morton, D. L., Weichselbaum R. R. (eds) Cancer medicine. 4th edn, Williams & Wilkins, Philadelphia, pp 799-815
20. Nogae, I., Kohno, K., Kikuchi, J., Kuwano, M., Akiyama, S., Kiue, A., Suzuki, K., Yoshida, Y., Cornwell, M. M., Pastan, I., Gottesman, M. M. (1989) Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. Biochem. Pharmacol. 38: 519-527
21. Ozben, T. (2006) Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580: 2903-2909
22. Philip, P. A., Joel, S., Monkman, S. C., Dolega-Ossowski, E., Tonkin, K., Carmichael, J., Idle, J. R., Harris, A. L. (1992) A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br. J. Cancer. 65: 267-270
23. Shamsipur, M., Hemmateenejad, B., Akhond, M., Javidnia, K., Miri, R. (2003) A study of the photo-degradation kinetics of nifedipine by multivariate curve resolution analysis. J. Pharm. Biomed. Anal. 31: 1013-1019
24. Straub, T., Boesenberg, C., Gekeler, V., Boege, F. (1997) The dihydropyridine dexniguldipine hydrochloride inhibits cleavage and relegation reactions of eukaryotic DNA topoisomerase I. Biochemistry 36: 10777-10783
25. Tanabe, H., Tasaka, S., Ohmori, H., Gomi, N., Sasaki, Y., Machida, T., Iino, M., Kiue, A., Naito, S., Kuwano, M. (1998) Newly synthesized dihydropyridine derivatives as modulators of P-glycoprotein-mediated multidrug resistance. Bioorg. Med. Chem. 6: 2219-2227
26. Teodori, E., Dei, S., Scapecchi, S., Gualtieri, F. (2002) The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Il Farmaco 57: 385-415
27. Thomas, H., Coley, H. M. (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159-165
28. Todeschini, R., Consonni, V. (eds) (2000) In: Mannhold, R., Kubinyi, H., Timmerman, H. (series eds) Handbook of molecular descriptors. Wiley-VCH, Weinheim, pp 513-514
29. Ueda, K., Cornwell, M. M., Gottesman, M. M., Pastan, I., Roninson, I. B., Ling, V., Riordan, J. R. (1986) The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem. Biophys. Res. Commun. 141: 956-962
30. Voigt, B., Coburger, C., Monar, J., Hilgeroth, A. (2007) Structure-activity analysis of novel N-acyloxy-1,4-dihydropyridines as P-glycoprotein inhibitors. Bioorg. Med. Chem. 15: 5110-5113
31. Walker, J. V., Nitiss, J. L. (2002) DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest. 20: 570-589
32. Zhou, X. F., Coburn, R. A., Morris, M. E. (2005a) Effects of new 4-aryl-1,4-dihydropyridines and 4-arylpyridines on drug efflux mediated by multidrug resistance-associated protein 1. J. Pharm. Sci. 94: 2256-2265
33. Zhou, X. F., Yang, X., Wang, Q., Coburn, R. A., Morris, M. E. (2005b) Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab. Dispos. 33: 1220-1228